|
|
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials
Thomas T. Aparicio
,
Michel Ducreux
,
Roger Faroux
,
Emilie Barbier
,
Sylvain Manfredi
et al.
Article dans une revue
hal-01983308v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
PFOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Final results of the FFCD 1102 phase II trial
J-B. Bachet
,
O. Lucidarme
,
C.B. Levache
,
E. Maillard
,
J.L. Raoul
et al.
Communication dans un congrès
hal-01632415v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
The epidemiology of Budd–Chiari syndrome in France
Isabelle Ollivier-Hourmand
,
Manon Allaire
,
Nathalie Goutte
,
Rémy Morello
,
Carine Chagneau-Derrode
et al.
Article dans une revue
hal-02057088v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial
J.B. Bachet
,
O. Lucidarme
,
C.B. Levache
,
E. Barbier
,
J.L. Raoul
et al.
Article dans une revue
hal-01960176v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Neoadjuvant FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A phase II multicentre randomised controlled trial (PRODIGE 22)
M. Karoui
,
A. Rullier
,
C. Mariette
,
E. Maillard
,
A. Bardier
et al.
Communication dans un congrès
hal-01632311v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|